Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs
The Journal of Clinical Psychiatry · 01.02.2023 · 84 (2)
DOI: 10.4088/jcp.22cr14598 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Psychiatry, online erschienen am 01.02.2023. Verfasst von Margarete A Wallner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rush Medical College, Chicago, Illinois. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rush Medical College, Chicago, Illinois.
- Corresponding author: Margarete A. Wallner, BS, Rush Medical College, 600 S Paulina St, Ste 403, Chicago, IL 60612 (margarete_a_wallner@rush.edu).
- Rush University Medical Center, Chicago, Illinois.
Zitieren
APA
Wallner, M. A., Eloge, J. C., Mackey, I. V., & Zajecka, J. (2023). Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs. The Journal of Clinical Psychiatry, 84(2). https://doi.org/10.4088/jcp.22cr14598
Vancouver
Wallner MA, Eloge JC, Mackey IV, Zajecka J. Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs. The Journal of Clinical Psychiatry. 2023;84(2). doi:10.4088/jcp.22cr14598
BibTeX
@article{Wallner2023,
author = {Wallner, Margarete A and Eloge, Joshua C and Mackey, Ian V and Zajecka, John},
title = {Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs},
journal = {The Journal of Clinical Psychiatry},
year = {2023},
volume = {84},
number = {2},
doi = {10.4088/jcp.22cr14598}
}
EUVIMED